ClinicalTrials.gg
RecruitingNCT02838602ETOILEUpdated Sep 2, 2021

Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

An interventional study of Carbon ions therapy and Advanced external radiotherapy by Xrays or protons in Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma, sponsored by Hospices Civils de Lyon. Recruiting at 21 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-02.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2017; still recruiting 8 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carcinoma, Adenoid Cystic with a site in France — 2 open to participants now, 2 under way, none of them phase 3. Carcinoma, Adenoid Cystic · France.

Started
2017
with 2 others
No phase
Only one
of the 10
Registered
4th of 10
by date
Lead sponsor
2 of 10
Hospices Civils de Lyon

Among the 10 studies in Carcinoma, Adenoid Cystic with a site in France, this one is one of 3 that started in 2017, is the only one with no phase, and was the 4th registered.

Carcinoma, Adenoid Cystic

86 studies on the registry are indexed under Carcinoma, Adenoid Cystic; 26 are open to participants now.

Browse Carcinoma, Adenoid Cystic studies →

Open to participants now

2 of the 10 studies in Carcinoma, Adenoid Cystic with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 23 Carcinoma, Adenoid Cystic studies recruiting now, 15 (65%) set no upper age limit and 3 (13%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Adenoid Cystic with a site in France, or all of them as a file.
02

Study summary

This is a transnational prospective randomized trial comparing definitive carbon ion therapy versus photon or combined photon and protontherapy as standard treatment for unresectable or macroscopically uncompleted resected radioresistant tumors. Eligible tumors are axial chordoma (except of base of skull), adenoid cystic carcinoma of head and neck (except of trachea) and sarcomas of any site (except chondrosarcoma of the skull base), non previously irradiated and without pre-planned surgery or chemotherapy after the clinical trial procedure. Randomization is balanced 1 for 1. Patients of the experimental arm are treated in carbon ions centers in Europe and patients of the standard arm are treated in France in their closest participating radiotherapy center. An accrual of 250 patients is needed and an absolute difference of 20% of relapse free survival at five years is awaited. The main endpoint is the progression free survival at five years. The trial is supported by the French program of clinical research and the national health insurance. Two associated studies are carried out: a radiobiological one looking for radioresistance markers in the sarcomas biopsies, and the second one is about medico economics.

03

Conditions studied

  • Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma

Keywords

  • carbon ions therapy
  • radiotherapy
  • radioresistant tumors
  • cancer
  • randomized trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 18 years
  • No severe comorbidity, above 10 years
  • Unresectable or inoperable or R2 resection of the tumor
  • Eligible radioresistant tumor according to the limitative list as following:

    • adenoid cystic carcinoma of head and neck (larynx and trachea excluded)
    • soft tissue sarcoma
    • pleomorphic rhabdomyosarcoma only (alveolar and embryonal forms excluded)
    • retroperitoneal sarcoma under condition of technical feasibility (movement)
    • osteosarcoma of any grade and localisation (Ewing excluded)
    • chondrosarcoma (except of skull base) OMS grade >= 2
    • chordoma axial skeleton or pelvis (except of skull base)
    • angiosarcoma
  • Absence of epidermal invasion (a hypodermic invasion is accepted with fixity of cutaneous plan but not true epidermal permeation)
  • Larger volume to be irradiated (PTV) less than 25 cm
  • Performance Status ≤ 2 or Karnovsky index ≥ 60
  • no pregnancy of possibility of pregnancy during the treatment
  • having an health insurance
  • signature of a written
  • validation of the randomization criteria: namely, a carbon ions therapy indication assessed by the medical team of a hadrontherapy center and able to by treated within two month from registration.

Exclusion criteria

Exclusion Criteria:

  • Complete macroscopic or microscopic surgical resection (R0 or R1)
  • previous irradiation in the volume to be treated
  • disease
  • disease not candidate to a curative approach (example accelerated progressive diseaseresistant to nay medical treatment especially for sarcoma)
  • any to undergo a radiation therapy by Xray or particle therapy
  • planned surgery or chemotherapy to take place after completion of radiotherapy (example : absence of enough space between an organ risk and the target volume (at least 5 mm) except the possibility of a spacer insertion)
  • planned surgery or chemotherapy after radiotherapy
  • Presence in the target volume of metallic material which cannot be removed (carbon fibres matreial authorized)
  • history of concomittant (except in situ cervix carcinoma; or any cured basocellular cutaneous cancer tor any cured cancer with no sign of relapse during 5 years))
  • impossible follow-up over 5 years
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Carbon ions therapy

    Radical and exclusive carbon ions radiotherapy

    Radiation: Carbon ions therapy

  • Active comparator
    Conventional radiotherapy

    Radical radiotherapy by Xrays and / or protons

    Radiation: Advanced external radiotherapy by Xrays or protons

Interventions

  • RadiationCarbon ions therapy

    External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center

  • RadiationAdvanced external radiotherapy by Xrays or protons

    Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Starting point for PFS measurement is the randomization date

    Time frame: up to 5 years or loss of follow-up

Secondary outcomes

  1. Grades of the CTCAE-V4.02 classification

    Tolerance

    Time frame: up to 5 years or loss of follow-up

  2. EQ-5D questionnaire

    Quality of life

    Time frame: up to 5 years or loss of follow-up

  3. Local progression free survival

    takes account of the local progression of the tumor in the planning target volume (PTV)

    Time frame: up to 5 years or loss of follow-up

  4. Metastases free survival

    takes account of any site of relapse outside of the PTV

    Time frame: up to 5 years or loss of follow-up

  5. Overall survival

    delay of death of any cause accounted starting from randomization

    Time frame: up to 5 years or loss of follow-up

07

Study locations

13 of 21 sites recruiting
  • CHU Amiens - Hôpital Sud
    Amiens, 80054, France
    Recruiting
    • Claude KRZISCH, MD · Contact
    • Claude KRZISCH, MD · Principal investigator
  • Radiothérapie, CLCC François Baclesse
    Caen, 14076, France
    Recruiting
    • Juliette THARIAT, MD · Contact
    • Juliette THARIAT, MD · Principal investigator
    • Dinu STEFAN, MD · Sub investigator
    • Delphine LEROUGE, MD · Sub investigator
    • Bernard GERY, MD · Sub investigator
    • Laura MOISE, MD · Sub investigator
    • Sabine NOAL, MD · Sub investigator
    • Jacques BALOSSO, MD · Sub investigator
  • Radiothérapie, CRLCC Jean Perrin
    Clermont-Ferrand, 63011, France
    Not yet recruiting
    • Fanny MARTIN · Contact
    • Fanny MARTIN, MD · Principal investigator
    • Michel LAPEYRE, MD · Sub investigator
    • Jessica MIROIR, MD · Sub investigator
  • Radiothérapie, CRLCC GF Leclerc
    Dijon, 21034, France
    Recruiting
    • Gilles TRUC, MD · Contact03.80.73.75.18
    • Gilles TRUC, MD · Principal investigator
    • Noémie VULQUIN, MD · Sub investigator
    • David THIBOUW, MD · Sub investigator
    • Caroline AMOYAL, MD · Sub investigator
  • Radiothérapie, Hôpital A. Michallon, CHU de Grenoble
    Grenoble, 38043, France
    Recruiting
    • Camille, Olivier VERRY, MD · Contact04.76.76.54.35
    • Camille, Olivier VERRY, MD · Principal investigator
    • Julie VILLA, MD · Sub investigator
    • Jacques BALOSSO, MD · Sub investigator
    • Carole IRIART, MD · Sub investigator
    • Violaine BRUN-BARONNAT, MD · Sub investigator
  • Radiothérapie, CRLCC Oscar Lambret
    Lille, 59020, France
    Recruiting
    • Xavier MIRABEL, MD · Contact03.20.29.55.98
    • Xavier MIRABEL, MD · Principal investigator
    • Raphaëlle MOUTTET-AUDOUARD, MD · Sub investigator
    • Abel CORDOBA, MD · Sub investigator
    • Xavier LIEM, MD · Sub investigator
    • David PASQUIER, MD · Sub investigator
  • Radiothérapie, CRLCC Léon Bérard
    Lyon, 69373, France
    Recruiting
    • Pascal POMMIER, MD · Contactpascal.pommier@lyon.unicancer.fr · (0)4 78 78 51 66
    • Pascal POMMIER, MD · Principal investigator
    • Marie-Pierre SUNYACH, MD · Sub investigator
    • Vincent GREGOIRE, MD · Sub investigator
  • Radiothérapie, CRLCC Institut Paoli Calmettes
    Marseille, 13009, France
    Not yet recruiting
    • Laurence MOUREAU-ZABOTTO, MD · Contact04.91.22.36.37
    • Laurence MOUREAU-ZABOTTO, MD · Principal investigator
  • Radiothérapie, Institut Régional du Cancer Montpellier, ICM Val d'Aurelle
    Montpellier, 34298, France
    Recruiting
    • Pierre BOISSELIER, MD · Contact
    • Pierre BOISSELIER, MD · Principal investigator
  • Pôle de radiothérapie, Centre Antoine-Lacassagne
    Nice, 06189, France
    Recruiting
    • Alexander FALK, MD · Contact
    • Alexander FALK, MD · Principal investigator
    • Jérôme DOYEN, MD · Sub investigator
    • Pierre-Yves BONDIAU, MD · Sub investigator
    • Karen BENEZERY, MD · Sub investigator
  • Radiothérapie, CHU Pitié-Salpétrière
    Paris, 75013, France
    Not yet recruiting
    • Loïc FEUVRET · Contact01.42.17.81.71
    • Loïc FEUVRET, MD · Principal investigator
  • Institut Curie, site Hôpital de Paris et site d'Orsay (Centre de protonthérapie)
    Paris, 75231, France
    Not yet recruiting
    • Rémi DENDALE, MD · Contact
    • Rémi DENDALE, MD · Principal investigator
    • Claire ALAPETITE, MD · Sub investigator
  • Radiothérapie, Hôpital de Haut Lévêque, CHU Bordeaux
    Pessac, 33604, France
    Not yet recruiting
    • Charles DUPIN, MD · Contact
    • Charles DUPIN, MD · Principal investigator
    • Huchet AYMERI, MD · Sub investigator
  • Radiothérapie, CRLCC Institut Jean Godinot
    Reims, 51726, France
    Recruiting
    • Stéphanie SERVAGI-VERNAT, MD · Contact
    • Stéphanie SERVAGI-VERNAT, MD · Principal investigator
  • Centre Eugene Marquis
    Rennes, 35000, France
    Not yet recruiting
    • Joël CASTELLI, MD · Contact
    • Joël CASTELLI, MD · Principal investigator
  • Radiothérapie, CRLCC René Gauducheau
    Saint-Herblain, 44805, France
    Not yet recruiting
    • Augustin MERVOYER, MD · Contact02.40.67.99.30
    • Augustin MERVOYER, MD · Principal investigator
    • Nadia WIAZZANE, MD · Sub investigator
  • Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirtz
    St Priest en Jarez, 42270, France
    Recruiting
    • Nicolas MAGNE, MD · Contact
    • Nicolas MAGNE, MD · Principal investigator
    • Amel REHAILIA-BLANCHARD, MD · Sub investigator
    • Grégoire PIGNE, MD · Sub investigator
  • Radiothérapie, CRLCC Paul Strauss
    Strasbourg, 67065, France
    Recruiting
    • Georges NOEL, MD · Contact03.88.25.24.71
    • Georges NOEL, MD · Principal investigator
  • Institut universitaire du cancer de Toulouse - Oncopole, Institut Claudius Regaud
    Toulouse, 31059, France
    Recruiting
    • Anne DUCASSOU, MD · Contact
    • Anne DUCASSOU, MD · Principal investigator
    • Anne LAPRIE, MD · Principal investigator
    • Martine DELANNES, MD · Sub investigator
  • Radiothérapie, Institut de Cancérologie de Lorraine Alexis Vautrin
    Vandœuvre-lès-Nancy, 54500, France
    Recruiting
    • Guillaume VOGIN, MD · Contact03.83.59.84.27
    • Guillaume VOGIN, MD · Principal investigator
    • Sophie RENARD, MD · Sub investigator
  • Radiothérapie, Institut Gustave Roussy
    Villejuif, 94805, France
    Not yet recruiting
    • Cécile LE PECHOUX, MD · Contact01.42.11.42.11
    • Cécile LE PECHOUX, MD · Principal investigator
    • Stéphanie BOLLE, MD · Sub investigator
08

References and documents

Publications

  • Balosso J, Febvey-Combes O, Iung A, Lozano H, Alloh AS, Cornu C, Herve M, Akkal Z, Lievre M, Plattner V, Valvo F, Bono C, Fiore MR, Vitolo V, Vischioni B, Patin S, Allemand H, Gueyffier F, Margier J, Guerre P, Chabaud S, Orecchia R, Pommier P. A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy - including photon and proton therapy - for the treatment of radioresistant tumors: the ETOILE trial. BMC Cancer. 2022 May 23;22(1):575. doi: 10.1186/s12885-022-09564-7. PubMed 35606739 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2017 (actual). Primary completion is estimated for Dec 2026, 108 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2016
First posted
Jul 20, 2016
StartActual
Dec 23, 2017
Primary completionEst.
Dec 23, 2026
CompletionEst.
Dec 23, 2026
Last update
Sep 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02838602
Responsible party
Sponsor
First posted
Jul 20, 2016
Start date
Dec 23, 2017
Primary completion
Dec 23, 2026 (estimated)
Completion
Dec 23, 2026 (estimated)
Last update
Sep 2, 2021

Study contacts

Pascal POMMIER, MD
Contact
pascal.pommier@lyon.unicancer.fr
(0)4 78 78 51 66 ext. +33
Pascal POMMIER, MD
principal investigator · Centre Leon Berard

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion